CHF 6297Alternative Names: CHF6297
Latest Information Update: 04 Jul 2016
At a glance
- Originator Chiesi Farmaceutici
- Class Corticosteroids
- Mechanism of Action Beta 2 adrenergic receptor agonists; Muscarinic receptor antagonists; P38 mitogen-activated protein kinase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Chronic obstructive pulmonary disease
Most Recent Events
- 01 Jan 2016 Phase-I/II clinical trials in Chronic obstructive pulmonary disease in United Kingdom (unspecified route) (NCT02815488)